StreetAlpha.app
Home › Stocks › OVID

Ovid Therapeutics Inc. (OVID)

Healthcare
$2.20
▼ −5.98%
LAST CLOSE · NOV 20

Ovid develops small molecule medicines for brain disorders such as epilepsy, seizure disorders and psychosis. It last closed at $2.20 on Nov 20, down 5.98% on the day. The next earnings report for OVID is expected around Wed, Mar 17, 2027. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months OVID insiders bought $0 of stock on the open market and sold $29K, according to SEC Form 4 filings.

AI Auto Pilots
Is OVID in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OVID.

Key Stats

Last 12 months
Results
Revenue
$1.5M
−78.0% vs a year ago
Net income
−$43.1M
−2967.2% margin
Operating margin
−4693.7%
−$68.2M operating income
Valuation
Market cap
$415.2M
188.7M shares
P/E
–
Price to sales
285.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$13.8M
At Sep 30
Shareholder equity
$198.7M
Shares outstanding
188.7M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $208.4M$208.4MFY2021FY2022: $1.5M$1.5MFY2022FY2023: $392K$392KFY2023FY2024: $566K$566KFY2024FY2025: $7.3M$7.3MFY2025

From OVID's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 17
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $76,000Dec '24Mar 2025: $130,000Mar '25Jun 2025: $6.3MJun '25Sep 2025: $132,000Sep '25Dec 2025: $718,000Dec '25Mar 2026: $0Mar '26Jun 2026: $733,000Jun '26Sep 2026: $0Sep '26Latest $0
How OVID moved after its last 8 reports
Average move the session after a report ±4.3%
Nov 10, 2026Time not announced−1.8%
Mar 18, 2026Time not announced+14.4%
Nov 12, 2025Time not announced−2.2%
May 13, 2025Time not announced−5.3%
Mar 11, 2025Time not announced+0.1%
May 14, 2024Time not announced+7.0%
Mar 8, 2024Time not announced−2.8%
Nov 3, 2023Time not announced+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OVIDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OVID
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OVID

Technical Analysis

OVID · as of the Nov 20 close · updated each morning
Turning down

The stock is 13% below its 20 day and 12% below its 50 day average. It is 11% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Jun 23) at $2.19, and the nearest resistance the Pivot at $2.23.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 9.8%/day
Key levels
$3.1052 week high+40.9%
$2.54100 day average+15.5%
$2.4920 day average+13.2%
$2.49Swing high (Oct 12)+13.2%
$2.4650 day average+11.8%
$2.43200 day average+10.5%
$2.29Pivot R1+4.1%
$2.23Pivot+1.4%
$2.20Last close
$2.19Swing low (Jun 23)−0.5%
$2.14Pivot S1−2.7%
$1.2152 week low−45.0%
Indicators
RSI (14)40.73Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic11.5Near the bottom of its rangeOversold
ADX (14)18.1No clear trend
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-98.0Oversold below −100, overbought above 100Neutral
Rate of change−22.8%Change over 10 sessionsBearish
ATR (14)$0.22Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OVID

What happened before

See how OVID did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OVID usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OVID has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OVIDHow many large options trades hit OVID, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

OVID Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲67 buying vs 44 selling
  • ▲Held by funds +0.9 pts
  • ▼Funds holding -2
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding129131−1.5%
In funds' top 1000–
Held by funds78.8%77.9%+0.9 pts
New / increased13 / 5446 / 33−15.2%
Reduced / sold out30 / 1427 / 18−2.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OVID institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OVID Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$29K2 sales · 2 insiders
2026-02 sold $29KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Feb 23Jeffrey A RonaCbfoSale8,541$1.45$12K
Feb 23Margaret A. AlexanderPresident and CEOSale11,656$1.45$17K
Feb 26, 2025Jeffrey A RonaCbfoSale3,902$0.56$2K
Feb 26, 2025Margaret A. AlexanderPresident and COOSale5,279$0.56$3K
Jan 27, 2025Margaret A. AlexanderPresident and COOBuy6,810$0.73$5K
Every insider buy and sale for OVID over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OVID insider trades →

From SEC Form 4 filings by OVID's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OVID is in one of them and how their past OVID trades turned out.

OVID in the AI portfolios
Loading…

OVID News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OVID in an article yet. Here's the latest on the wider market.

OVID in the news

About Ovid Therapeutics

Ovid is a biopharmaceutical company that develops small molecule medicines for disorders of the brain and nervous system. Its work centers on epilepsy, seizure disorders and psychosis, with medicines designed to calm overactive nerve cells. Its programs are in clinical trials, and the company aims to serve patients with seizure and psychiatric conditions that have few treatment options. Ovid is based in New York.

Headquarters
New York, NY